Document Detail


A Fresh Perspective on Comparing the FDA and the CHMP/EMA: Approval of antineoplastic tyrosine kinase inhibitors.
MedLine Citation:
PMID:  23362829     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
We compared, and determined the reasons for any differences in, the review and approval times of tyrosine kinase inhibitors (TKI) by the FDA and the EMA/CHMP. Applications for these novel cancer drugs were submitted to them within a mean of 31.2 days of each other, providing a fair basis for comparison. The FDA had granted priority review to 12 TKIs but the EMA/CHMP did not grant the equivalent accelerated assessment to any. The FDA granted accelerated approvals to 6 (38%) and CHMP granted (the equivalent) conditional approvals to 4 (29%) of these agents. On average, the review and approval times were 205.3 days in the US compared to 409.6 days in the EU. The active 225.4 days in the EU and 205.3 days in the US). Since oncology drug development lasts about 7 years, the 20-days difference in review times between the two agencies is inconsequential. Clock stops during review and the time required to issue an approval had added the extra 184.2 days to review times, however were comparable (review time in the EU. We suggest possible solutions to expedite the EU review and approval processes. However, post-marketing emergence of adverse efficacy and safety data on gefitinib and lapatinib, respectively, indicate potential risks of expedited approvals. We challenge the widely prevalent myth that early approval translates into early access or beneficial impact on public health. Both the agencies collaborate closely but conduct independent assessments and make decisions based on distinct legislation, procedures, precedents, and societal expectations.
Authors:
Rashmi R Shah; Samantha A Roberts; Devron R Shah
Related Documents :
16514129 - Bos morth cases prize 2004.
8123319 - Replantation in general dental practice.
15206259 - Mandibular second molar with c-shaped canal morphology and five canals: report of a case.
18059249 - Third canal in the mesial root of permanent mandibular first molars: review of the lite...
7673999 - Y-shaped lower bilateral incisors. a previously undescribed oral malformation.
16149929 - Odontoma-like malformation in a permanent maxillary central incisor subsequent to traum...
6644509 - Meconium thorax.
9231099 - Simultaneous occurrence of metastatic tonsillar squamous cell carcinoma and angioimmuno...
22953649 - Traumatic forequarter amputation associated acute lung injury (ali): report of one case.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-31
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  -     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 The Authors. British Journal of Clinical Pharmacology © 2013 The British Pharmacological Society.
Affiliation:
Rashmi Shah Consultancy Ltd, Gerrards Cross, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Physical exercise intervention in depressive disorders: Meta-analysis and systematic review.
Next Document:  Metformin Induces Cytotoxicity by Down-Regulating Thymidine Phosphorylase and ERCC1 Expression in No...